New Bitter C27 and C30 Terpenoids from the Fungus Ganoderma lucidum (Reishi)

Four new bitter terpenoids, lucidenic acids A (1), B (2), C (3) and ganoderic acid C (5), were isolated from the fruiting bodies of Ganoderma lucidum, together with the known bitter ganoderic acid B (4). On the basis of spectroscopic data and chemical conversion, their structures were determined to be 7β-hydroxy-4,4,14α-trimethyl-3,11,15-trioxo-5α-chol-8-en-24-oic acid, 7β,12β-dihydroxy-4,4,14α-trimethyl-3,11,15-trioxo-5α-chol-8-en-24-oic acid, 3β,7β,12β-trihydroxy-4,4,14α-trimethyl-11,15-dioxo-5α-chol-8-en-24-oic acid and 7β-hydroxy-3,11,15,23-tetraoxo-5α-lanost- 8-en-26-oic acid, respectively.     

Ganoderiol A and B,New Triterpenoids from the Fungus Ganoderma lucidum (Reishi)

Two new lanostane-type triterpenoids, ganoderiol A (1) and ganoderiol B (2) were isolated from the fruiting bodies of Ganoderma lucidum, together with known ganodermanontriol (3) and ganodermatriol (4). The compounds were identified as 5α-lanosta-7,9(11)-dien-3β,24,25,26-tetraol (1), 15α,26,27-trihydroxy-5α-lanosta-7,9(11),24-trien-3-one (2), 24,25,26-trihydroxy-5α-lanosta-7,9(11)-dien-3-one (3) and 5α-lanosta-7,9(ll),24-trien-3β,26,27-triol (4), respectively.     

Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides

We describe here the isolation of Reishi polysaccharides for the study of their effect on cytokine expression in mouse splenocytes. A fraction (F3) has been shown to activate the expression of IL-1, IL-6, IL-12, IFN-gamma, TNF-alpha, GM-CSF, G-CSF, and M-CSF, and from this three subfractions have been prepared where F3G1 activates IL-1, IL-12, TNF-alpha, and G-CSF, F3G2 activates all the cytokines as F3 does, and F3G3 activates only IL-1 and TNF-alpha. Together with previous studies, the mode of action on macrophages has been proposed where F3 binds to TLR4 receptor and activates extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 to induce IL-1 expression.     

灵芝孢子油脂肪酸组分的分析

采用气相色谱与质谱(GC-MS)联用分析,从超临界CO2萃取孢子油中鉴定出18种脂肪酸成分,包括6种不饱和脂肪酸、7种饱和脂肪酸、2种环链脂肪酸,以及己酸、辛酸、壬酸等短链脂肪酸。GC定量分析结果表明:灵芝孢子油中检出9种已知脂肪酸,不饱和脂肪酸总量为73.6%;其中,主体成分油酸(C18∶1)、亚油酸(C18∶2)和棕榈酸(C16∶0)等含量分别为57.5%、13.4%、19.6%;此外,不饱和脂肪酸十六碳烯酸(C16∶1)、亚麻酸(C18∶3)等不饱和脂肪酸含量为2.2%、0.5%。     

灵芝的开发及加工研究新进展

综述了近几年来国内外灵芝产品的开发研究及加工近况 ,探讨当前灵芝开发过程中存在的问题。     

Anti-Tumor Effects of Ganoderma lucidum (Reishi) in Inflammatory Breast Cancer in In Vivo and In Vitro Models

The medicinal mushroom Ganoderma lucidum (Reishi) was tested as a potential therapeutic for Inflammatory Breast Cancer (IBC) using in vivo and in vitro IBC models. IBC is a lethal and aggressive form of breast cancer that manifests itself without a typical tumor mass. Studies show that IBC tissue biopsies overexpress E-cadherin and the eukaryotic initiation factor 4GI (eIF4GI), two proteins that are partially responsible for the unique pathological properties of this disease. IBC is treated with a multimodal approach that includes non-targeted systemic chemotherapy, surgery, and radiation. Because of its non-toxic and selective anti-cancer activity, medicinal mushroom extracts have received attention for their use in cancer therapy. Our previous studies demonstrate these selective anti-cancer effects of Reishi, where IBC cell viability and invasion, as well as the expression of key IBC molecules, including eIF4G is compromised. Thus, herein we define the mechanistic effects of Reishi focusing on the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, a regulator of cell survival and growth. The present study demonstrates that Reishi treated IBC SUM-149 cells have reduced expression of mTOR downstream effectors at early treatment times, as we observe reduced eIF4G levels coupled with increased levels of eIF4E bound to 4E-BP, with consequential protein synthesis reduction. Severe combined immunodeficient mice injected with IBC cells treated with Reishi for 13 weeks show reduced tumor growth and weight by ∼50%, and Reishi treated tumors showed reduced expression of E-cadherin, mTOR, eIF4G, and p70S6K, and activity of extracellular regulated kinase (ERK1/2). Our results provide evidence that Reishi suppresses protein synthesis and tumor growth by affecting survival and proliferative signaling pathways that act on translation, suggesting that Reishi is a potential natural therapeutic for breast and other cancers.     

Potential of waste reduction of agro-biomasses through Reishi medicinal mushroom (Ganoderma lucidum) production using different substrates and techniques

One of the most important priorities in the medicinal mushrooms cultivation is the selection and preparation of the substrate, which depends on factors such as price and easy access to different lignocellulosic compounds. In order to investigate the effect of mixed and non-mixed agro-waste substrates on some vegetative, reproductive, nutritional and medicinal properties of two Iranian and Chinese strains of Ganoderma lucidum, the factorial experiment was conducted as a completely randomized design with three replications. The experimental substrates of different poplar wood chip (PWC), wheat bran (WB), soybean meal (SM), date palm leaf (DPL) and olive oil extraction waste (OOEW) were used. They were enriched with chemical supplements (ammonium nitrate, manganese sulfate and Nano manganese oxide) using two cultivation techniques (open bag door and Polika-Cotton) for fruiting body production.The results showed that various substrates significantly affect dry weight, moisture content quantity, vegetative and fruit yield, total ganoderic acids content, total polysaccharide value and mineral elements amount (nitrogen, potassium and calcium) in fruiting body. The highest amount of N content in the fruiting body of both Iranian and Chinese strains (5.88 and 6.25 mg/100 g dry matter) was dedicated to the combined PWC + SM (70:30) substrate enriched with Nano manganese oxide supplement and Polika-Cotton method. The highest total fresh of Iranian and Chinese strains weight (109.60 and 127.66 g, respectively) obtained in the combined PWC + WB (70:30) substrate enriched with manganese sulfate. The highest amount of total ganoderic acids in fruiting organs in both strains (0.52 and 0.42 μg/mg dry matter) is achieved using a combined PWC + SM (70:30) enriched with manganese sulfate.     

C27-Nor lanostane triterpenoids of the fungus Ganoderma lucidum and their inhibitory effects on acetylcholinesteras

The lanostane nor-triterpenoids (ganoderic acids) of the functional food and folk medicine Ganoderma lucidum have been investigated by chromatographic techniques and spectroscopic data analysis. Nineteen nor-ganoderic acid analogues were obtained and identified, yielding five new lanostane analogues (1–4 and 11). All of the triterpenoids were systemically evaluated for their inhibitory effects against AChE (acetylcholinesterase) in vitro. Triterpenoid 16 was the most potent compound with the IC₅₀ value of 54.5 μM. The docking analysis has been performed to reveal the interaction between ganoderic acid 16 and AChE for developing the new inhibitors of AChE.     

Triterpenoids from the fungus Ganoderma lucidum

Ten novel components, ganoderic acid, ganoderenic acid and lucidenic acid derivatives, were isolated from the fruiting body of the fungus Ganoderma lucidum. Their structures were elucidated mainly by spectroscopic and chemical methods.     

Ganodermasides C and D,Two New Anti-Aging Ergosterols from Spores of the Medicinal Mushroom Ganoderma lucidum

Two new anti-aging compounds, ganodermasides C and D, were isolated and their structures elucidated. They are novel ergosterols possessing a 4,6,8(14),22-tetraene-3-one unit with unique hydroxylation at C-9. Both of them significantly extended the replicative lifespan of the K6001 yeast strain. Ganodermasides C and D regulated the expression of the gene for UTH1 to prolong the replicative lifespan of yeast.     

Purification and characterization of lectin from fruiting body of Ganoderma lucidum: lectin from Ganoderma lucidum

A novel 114 kDa hexameric lectin was purified from the fruiting bodies of the mushroom Ganoderma lucidum. Biochemical characterization revealed it to be a glycoprotein having 9.3% neutral sugar and it showed hemagglutinating activity on pronase treated human erythrocytes. The lectin was stable in the pH range of 5-9 and temperature up to 50 degrees C. The hemagglutinating activity was inhibited by glycoproteins that possessed N-as well as O-linked glycans. Chemical modification of the G. lucidum lectin revealed contribution of tryptophan and lysine to binding activity. The thermodynamics of binding of bi- and triantennary N-glycans to G. lucidum lectin was studied by spectrofluorimetry. The lectin showed very high affinity for asialo N-linked triantennary glycan and a preference for asialo glycans over sialylated glycans. The binding was accompanied with a large negative change in enthalpy as well as entropy, indicating primarily involvement of polar hydrogen, van der Waals and hydrophobic interactions in the binding.     

New Triterpenoids from the Fruiting Bodies of Ganoderma lucidum and Their Bioactivities

Phytochemical investigation of the AcOEt extract of G. Lucidum has led to the isolation of two new triterpenoids, 1 and 2 , together with five known ones, 3 – 7 . The structures of the new compounds were identified as 12β‐acetoxy‐3β,7β‐dihydroxy‐11,15,23‐trioxolanost‐8‐en‐26‐oic acid butyl ester ( 1 ) and 12β‐acetoxy‐3,7,11,15,23‐pentaoxolanost‐8‐en‐26‐oic acid butyl ester ( 2 ) on the basis of detailed spectroscopic analysis (mass spectrometry, and 1D‐ and 2D‐NMR experiments). The antimicrobial activities of 1 and 2 were also evaluated.     

Cloning and characterization of squalene synthase (SQS) gene from Ganoderma lucidum

This report provides the complete nucleotide sequences of the full-length cDNA encoding squalene synthase (SQS) and its genomic DNA sequence from a triterpene-producing fungus, Ganoderma lucidum. The cDNA of the squalene synthase (SQS) (GenBank Accession Number: DQ494674) was found to contain an open reading frame (ORF) of 1,404 bp encoding a 468-amino-acid polypeptide, whereas the SQS genomic DNA sequence (GenBank Accession Number: DQ494675) consisted of 1,984 bp and contained four exons and three introns. Only one gene copy was present in the G lucidum genome. The deduced amino acid sequence of Ganoderma lucidum squalene synthase (Gl-SQS) exhibited a high homology with other fungal squalene synthase genes and contained six conserved domains. A phylogenetic analysis revealed that G. lucidum SQS belonged to the fungi SQS group, and was more closely related to the SQS of U. maydis than to those of other fungi. A gene expression analysis showed that the expression level was relatively low in mycelia incubated for 12 days, increased after 14 to 20 days of incubation, and reached a relatively high level in the mushroom primordia. Functional complementation of Gl-SQS in a SQS-deficient strain of Saccharomyces cerevisiae confirmed that the cloned cDNA encoded a squalene synthase.     

Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities

A fucose-containing glycoprotein fraction which stimulates spleen cell proliferation and cytokine expression has been identified from the water-soluble extract of Ganoderma lucidum. Proteomic analysis of mouse spleen cells treated with this glycoprotein fraction showed approximately 50% change of the proteome. Further studies on the activities of this glycoprotein fraction through selective proteolysis and glycosidic cleavage indicate that a fucose containing polysaccharide fraction is responsible for stimulating the expression of cytokines, especially IL-1, IL-2 and INF-gamma.     

赤芝一共生菌发酵过滤液中的新倍半萜酯

从四川野生赤芝(Ganoderma lucidum (Leyss. ex Fr.) Karst.)的一共生菌Calcarisporium arbuscula Preuss的发酵过滤液中分离得到3个新的倍半萜酯类化合物,分别命名为calcarisporin B2 (1)、B3 (2)和B4 (3),通过物理方法和波谱分析确定了它们的结构.